Relationship Between Bone Mineral Density T ‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment-Reference-Cited by-同舟云学术

Relationship Between Bone Mineral Density T ‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

Published:2019-05-29 Issue:6 Volume:34 Page:1033-1040
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Ferrari S¹,Libanati C²,Lin Celia Jow Fang³,Brown JP⁴,Cosman F⁵,Czerwiński E⁶,Gregόrio LH⁷,Malouf‐Sierra J⁸,Reginster J‐Y⁹,Wang A³,Wagman RB³,Lewiecki EM¹⁰

Affiliation:

1. Geneva University Hospital Geneva Switzerland

2. UCB Pharma Brussels Belgium

3. Amgen Inc. Thousand Oaks CA USA

4. Laval University and CHU de Québec Research Centre Quebec City QC Canada

5. Columbia University NY USA

6. Krakow Medical Center Krakow Poland

7. Center for Clinical and Basic Research – Brasil Rio de Janeiro Brazil

8. Universitat Autònoma de Barcelona Barcelona Spain

9. University of Liège Liège Belgium

10. New Mexico Clinical Research & Osteoporosis Center Albuquerque NM USA

Funder

Amgen

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jbmr.3722

Reference31 articles.

1. 6. Glycemic Targets

2. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Whelton PK;Hypertension,2017

3. Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?

4. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study

5. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Goal-directed osteoporosis treatment: ASBMR/BHOF task force position statement 2024;Journal of Bone and Mineral Research;2024-07-29

2. Mechanistic Insights and Therapeutic Strategies in Osteoporosis: A Comprehensive Review;Biomedicines;2024-07-23

3. Letter to the Editor From Fitzpatrick et al: “Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than A Single Infusion?”;The Journal of Clinical Endocrinology & Metabolism;2024-07-15

4. Response to: Letter to the Editor From Fitzpatrick et al: “Zoledronate After Denosumab Discontinuation: Is Repeated Administrations More Effective Than Single Infusion?”;The Journal of Clinical Endocrinology & Metabolism;2024-07-15

5. Develop a bone mineral density T-score distribution nomograms based on osteoporosis risk factors for middle-aged and older adults;Geriatric Nursing;2024-07